Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms × abexinostat × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Neoplasm Metastasis 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Hodgkin Disease 2 Ureteral Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Oligodendroglioma 1 Neoplasms by Site 1 Neoplasms 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Disease Progression 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Bronchiolitis Obliterans Syndrome 1 Astrocytoma 1

Interventions

pembrolizumab 155 Gemcitabine 146 Paclitaxel 134 Carboplatin 120 Bevacizumab 116 Docetaxel 100 Cyclophosphamide 100 Cisplatin 99 Exercise 82 Nivolumab 81 Capecitabine 80 Fluorouracil 78 Dexamethasone 74 Irinotecan 68 Oxaliplatin 62 Pemetrexed 60 Radiotherapy 59 Leucovorin 57 Standard of Care 56 Cetuximab 50 Blood Specimen Collection 48 Sorafenib 47 Drug Therapy 47 Erlotinib Hydrochloride 46 Doxorubicin 44 atezolizumab 41 130-nm albumin-bound paclitaxel 39 trametinib 37 Ipilimumab 36 Albumin-Bound Paclitaxel 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03600441 2025-04-10

FORERUNNER

Xynomic Pharmaceuticals, Inc.

Phase 2 Active not recruiting

Lymphoma, Follicular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡